Article: Orchid Receives First Approval to Use SNP Technology as Primary Markers for Paternity Testing.

Orchid BioSciences, Inc. today announced that it is the first company to receive approval from the American Association of Blood Banks (AABB) to use single nucleotide polymorphisms (SNPs) as stand-alone genetic markers in its Orchid GeneScreen paternity testing operations. Orchid is replacing conventional short tandem repeat, or STR techniques with more cost-effective methods that use its SNP genotyping technology to achieve additional efficiencies and further improve quality and service in its paternity testing operations. The AABB is the leading standard-setting organization for parentage testing in the U.S.

Orchid expects the application of its technology to ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!